NICE recommends reimbursement for Jetrea in England, Wales

The final ruling recommended reimbursing Jetrea (ocriplasmin, ThromboGenics/Alcon) for patients with vitreomacular traction and full-thickness macular holes up to 400 µm in diameter in the absence of epiretinal membrane.The ruling also recommended reimbursing Jetrea when used to treat patients with metamorphopsia, an early symptom of vitreomacular traction.

Full Story →